Gainers
Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) gained 53.3% to $166.41 after Biogen agreed to acquire the company.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares gained 48.5% to $7.95.
AEye, Inc. (NASDAQ: LIDR) shares climbed 48.5% to $0.3300 after falling around 4% on Thursday.
View, Inc. (NASDAQ: VIEW) gained 40.4% to $15.45.
Infobird Co., Ltd (NASDAQ: IFBD) gained 40% to $1.17.
Business First Bancshares, Inc. (NASDAQ: BFST) rose 28% to $21.77 following upbeat quarterly results.
Gracell Biotechnologies Inc. (NASDAQ: GRCL) climbed 24.3% to $3.9898.
INVO Bioscience, Inc. (NASDAQ: INVO) gained 23% to $4.6189. INVO BioScience recently announced 1-for-20 reverse stock split.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) gained 22% to $1.3115. Mersana Therapeutics said that the UPLIFT clinical trial of upifitamab rilsodotin did not meet its primary endpoint.
Roku, Inc. (NASDAQ: ROKU) jumped 20.8% to $82.43 after the company reported better-than-expected second-quarter results and issued strong third-quarter guidance.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) rose 20.5% to $3.75.
Homology Medicines, Inc. (NASDAQ: FIXX) shares climbed 19.7% to $1.1250. Homology Medicines announced initial data from the first dose cohort in the pheEDIT Phase 1 dose-escalation trial evaluating gene editing candidate HMI-103 in adults with classical phenylketonuria (PKU). Homology will not be further developing its programs and will be instituting a related reduction in force while it explores options for the company and its assets, including HMI-103. The company is reducing its workforce by 87% and stopping further program development efforts outside of required actions, including continued collection of data from and monitoring of participants in its clinical trials.
Huron Consulting Group Inc. (NASDAQ: HURN) gained 18.5% to $94.00 following upbeat quarterly results.
TAL Education Group (NYSE: TAL) climbed 18.1% to $7.57. TAL ...
Benzinga
